Shareholders meeting

July 18, 2026 The Manager - Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 The Manager - Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai - 400001 Dear Sir/ Madam, Sub: Notice of the 47th Annual General Meeting Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 47th Annual General Meeting of the Company scheduled to be held on Monday, August 10, 2026 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent through electronic mode to those Members who have registered their email ID with the Company/ Depositories/Registrar and Share Transfer Agent of the Company. Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, a physical communication containing the weblink for accessing the Notice of the AGM and Annual Report for the financial year ended March 31, 2026 is being sent to those Members whose email addresses are not registered. The said Notice along with the Annual Report for the financial year ended March 31, 2026 is also available on the website of the Company at www.astrazeneca.com/india. This is for your kind information and records. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No. 25784 Encl: as above AstraZeneca Pharma India Limited AstraZeneca Pharma India Limited Registered Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore – 560 045 CIN: L24231KA1979PLC003563, Web: www.astrazeneca.com/india E-mail: comp.secy@astrazeneca.com, Tel: +91 80 6774 8000 Notice Statutory Auditors of the Company to hold office for a term of 5 (five) consecutive years from the conclusion of this 47th Annual General Meeting till the conclusion of 52nd Annual NOTICE is hereby given that the 47th Annual General General Meeting of the Company to be held in the calendar Meeting of the Members of AstraZeneca Pharma year 2031, at such remuneration as may be approved by India Limited will be held on Monday, August 10, 2026 the Board of Directors (which term shall include its duly at 3:00 PM through Video Conferencing (‘VC’)/Other empowered Committee(s)) from time to time. Audio-Visual Means (‘OAVM’) to transact the following business: RESOLVED FURTHER THAT the Board of Directors of the Company, be and are hereby authorized to do all such acts, ORDINARY BUSINESS deeds, matters and things and to take all such steps as may Item No. 1 be required and to execute all documents, applications, To receive, consider and adopt the Audited Financial returns and writings as may be necessary, proper, desirable Statements of the Company for the financial year ended or expedient to give effect to this resolution or for the matters March 31, 2026 and the Reports of the Board of Directors connected therewith or incidental thereto.” and Auditors thereon. Item No. 5 Item No. 2 Re-appointment of Ms. Shilpa Divekar Nirula as an To declare Dividend of Rs. 36/- per share on equity shares Independent Director for the financial year 2025-26. To consider and if thought fit, to convey assent or dissent to the following Special Resolution: Item No. 3 RESOLVED THAT pursuant to the provisions of Sections To appoint a Director in place of Ms. Bhavana Agrawal (DIN: 149, 152 read with Schedule IV and other applicable 10485441) who retires by rotation, and being eligible, offers provisions of the Companies Act, 2013 (the ‘Act’) read with herself for re-appointment. the Companies (Appointment and Qualifications of Directors) SPECIAL BUSINESS Rules, 2014 and any other rules, circulars, notifications, etc. issued under the Act (including any statutory modification(s) Item No. 4 or re-enactment(s) thereof for the time being in force), Appointment of Statutory Auditors of the Company Regulations 17, 25 and other applicable provisions, if any, of To consider and if thought fit, to convey assent or dissent to the SEBI (Listing Obligations and Disclosure Requirements) the following Ordinary Resolution: Regulations, 2015 including any amendment(s) thereto (‘SEBI RESOLVED THAT pursuant to the provisions of Sections Listing Regulations’), and the Articles of Association of the 139, 142 and other applicable provisions, if any, of the Company, Ms. Shilpa Divekar Nirula (DIN: 06619353), who Companies Act, 2013 read with the Companies (Audit and was appointed as an Independent Director of the Company Auditors) Rules, 2014 including any statutory modification(s) for a period of five years with effect from December 29, or re-enactment thereof for the time being in force, the 2021 and who holds office up to December 28, 2026 and applicable provisions of the Securities and Exchange Board who meets the criteria for independence as provided in of India (Listing Obligations and Disclosure Requirements) Section 149(6) of the Act and the Rules made thereunder Regulations, 2015 as amended from time to time, and and Regulation 16(1)(b) of the SEBI Listing Regulations and based on the recommendation of the Audit Committee in respect of whom the Company has received a notice and the Board of Directors of the Company, M/s. BSR & in writing under Section 160 of the Act from a member Co. LLP, Chartered Accountants (Firm Registration No. proposing her candidature for the office of Director, being 101248W/W-100022), be and are hereby appointed as the eligible, be and is hereby re-appointed as an Independent 30 | Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements Director, not liable to retire by rotation to hold office for as may be necessary, proper, desirable or expedient to a second term of 5 (five) consecutive years commencing give effect to this resolution or for the matters connected from December 29, 2026 to December 28, 2031 (both days therewith or incidental thereto. inclusive). By Order of the Board of Directors RESOLVED FURTHER THAT approval of the Members be For AstraZeneca Pharma India Limited and is hereby accorded to the Board of Directors (which term shall include its duly empowered Committee(s)) to do all such Tanya Sanish acts, deeds, matters and things and to take all such steps Place: Bengaluru Company Secretary as may be required and to settle any questions, difficulties Date: May 26, 2026 Membership No.: A25784 or doubts that may arise in this regard and further to execute all necessary documents, applications, returns and writings Notes: 1) Pursuant to the Ministry of Corporate Affairs (‘MCA’) the same at their depository participant where they General Circular dated May 5, 2020 read with circulars are have their account and Members holding shares in dated April 8, 2020, April 13, 2020, and subsequent physical mode kindly send the KYC documents to the circulars issued in this regard, the latest one being RTA address to register their e-mail id and KYC details. circular no. 03/2025 dated September 22, 2025, issued In case of any queries, Member may write to irg@ by the Ministry of Corporate Affairs (collectively referred integratedindia.in. to as ‘MCA Circulars’), MCA has permitted the holding 5) Members are also requested to register their e-mail of the Annual General Meeting (‘AGM’) through VC/ address, in respect of electronic holdings with the OAVM, without the physical presence of the members Depositories/Depository Participant and in respect of at a common venue. In compliance with the provisions physical holdings with the RTA. of the Companies Act, 2013 (‘the Act’), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 6) Pursuant to the MCA Circulars, the facility to appoint 2015 (‘the Listing Regulations’) and MCA Circulars, the proxy to attend and cast vote for the Members is not AGM of the Company is being held through VC/OAVM. available for this [Showing first 8,000 characters — download PDF for full document]